FK-506抑制高危角膜移植免疫排斥反应的研究

目的 :探讨FK -5 0 6抑制高危角膜移植免疫排斥反应临床应用的可行性及有效性。方法 :应用前瞻性评估研究方法 ,将行高危角膜移植术 (全角膜移植术、带巩膜环的全角膜移植术、血管化角膜的角膜移植术及角膜再移植术 ) 5 6例 (5 6只眼 )患者按随机原则进行分组 (投药组及对照组 ) ,投药组 (2 8只眼 )滴用 0 5mg/ml的FK -5 0 6滴眼液联合典必珠滴眼液 ,对照组 (2 8只眼 )滴用 1%CsA滴眼液联合典必殊滴眼液 ;平均随访 8 1个月 ,以术后视功能、植片透明维持时间、植片新生血管、水肿及混浊程度作为临床主要评估指标。结果 :随防期内投药组及对照组角膜移植片免疫排斥反应发生率分别为 63 6%及 95 2 % ,差异有显著性 (χ2 =4 72 ,P <0 0 5 )。用药期间未发现该药有任何毒副作用。结论 :局部应用FK -5 0 6可有效抑制高危角膜移植免疫排斥反应的发生。

Immunosuppresant FK- 506 on the high- risk penetrating keratoplasty rejection

Objective:To evaluate the clinical probability and efficacy of FK-506 on suppressing cornea transplantation rejection. Methods:A prospective,random study was carried out.The 56 cases (56 eyes) with high-risk keratoplasty were randomly divided into trial group and control group.The trial group was treated by FK-506 eyedrops (0 5mg/ml) and TobraDex eyedrops;control group was treated by 1% CsA eyedrops and TobraDex eyedrops.As index,the postoperative visual function,graft transparent duration,neovascularization,edema and opacity were observed in average 8.1 months follow up. Results:Within the follow up,the graft rejection rate of the two groups were 63 6% and 95 2%,respectively (P<0 05). Conclusions:The topical application of FK-506 suppressed effectively the postoperative graft rejection of high-risk cornea transplantation.